Investment Banking World 228

Use the valuation model, updating the 'Per Share' and 'Premium' values for the low, mid, and high cases to reflect Blackstone’s acquisition of Company X and the assumptions below. Reply back to me with the per share data in € and the Premium. Round percentages to 1 decimal place. Assumptions to follow - Blackstone acquired Company X in 2020 at an EV of €1000M - Company X revenue was €100M - Company X EBITDA was €50M - Blackstone acquired Company X at a 45% premium - The Stevanato - SVM Automatik transaction is an outlier and should be excluded from the analysis - The Mid EV/EBITDA multiple is the average of the High and Low multiples - Gerresheimer recently completed a capital raise that is not reflected in the base case, issuing10 million shares at €30.00 per share - Gerresheimer used €200M of the proceeds raised to acquire 49% of Company Y that has €50M in EBITDA

Assume that 10% of Aptar's Asian pharma revenue will shift entirely into European pharma revenue. Retroactively apply this to 2024 financials. Refer to the 2024 ATR report. Return a short message with the values for Asia Pharma and Europe Pharma for their corresponding revenue under this set of assumptions. Round dollar amounts to the nearest thousand.

From Becton Dickinson's FY2025 Annual Report assume the FDA finds that one violation regarding the Alaris SE infusion pumps, and decides the company is in violation, and enforces the consent decree on Alaris SE infusion pumps from November 29, 2024, to November 28, 2025, inclusive. Compute the average dollar burden of the penalty on BDX average shareholder. Output the result in USD as a reply to me here, rounded to 4 decimal places. Assume a 30-day month and a 360-day year.

Please access the 2024 Huhtamaki Annual Report and calculate the Net Sales per employee at end of period for 2023 and 2024. Reply to me here with the the Euros per Employee, rounded to the nearest full Euro amount.

The current standalone DCF valuation does not include synergies. In the valuation model, re-run the analysis to include synergies, integration, and transaction costs. In the accretion dilution model project, the "Synergies" and "ProForma_Combined" tabs contain these assumptions. 1. Update the vauation model "Project_Rheingold_Valuation_Model(final)" 2. Implement One-Time Integration Costs (After-Tax), Transaction Costs (After-Tax), and EBITDA Synergy (pre-tax) into the DCF analysis, maintaining all existing DCF assumptions. 3. Report back for me: "Sum of PV of FCF (2026-2030)", "PV of Terminal Value", "Enterprise Value", "Implied EV/EBITDA(2025E)", "Implied EV/Revenue(2025E)". 4. Round all final monetary values (millions) and multiples to one decimal place.

If the value of ATRs holdings of Goldrain and YAT appreciated by 5% and 10% respectively, from the end of 2024, while all other equity investments remained constant, what would the new total value of ATR equity investments be? You should respond here with a single dollar amount. Round to the nearest thousand and return the complete dollar amount. Reference the 2024 ATR report for all required information. Write out right here for me what I need.

Using the 2024 ATR annual report, analyze the results of a 15% tariff on Aptar Group’s FY2024 net income. Assume the 15% applies only to Cost of Sales, exclusive of depreciation and amortization. Round all values to the nearest thousand. Use a 20.35% tax rate. Output just the pro-forma net income as a reply here.

In The Aptar Group's 2024 annual report, extract global revenue for the Pharma segment in 2023 and 2024. Compute the aggregate dollar change in thousands of USD adjusted for 7.1% 2024 global inflation and express the result in USD, rounded to the nearest thousand. Print back to me what you find please.

Using the 2024 ATR annual report, reply to me with the absolute performance difference between ATR shares and the Peer Group in 2024 as a percentage (round this to two decimal places).

You have access to the accretion dilution model. Create a new sheet and tell me the Proforma Interest Coverage for 2027 and 2028. In doing so, assume: - Aptar's Interest expense as a percentage of sales in sheet "Aptar_Historicals" is now 2% for the projection period (2025E - 2030E) - Aptar's Total OPEX as a percentage of sales in sheet "Aptar_Historicals" is now 25% for the projection period (2025E - 2030E) - Aptar's Tax Rate as a percentage of sales in sheet "Aptar_Historicals" is now 35% for the projection period (2025E - 2030E) - Interest on Existing debt remains unchanged. - Cost synergies target in sheet "Synergies" is 35% - Synergies in sheet "Synergies" will be 50% realized in 2025, 2026 and 2027 and 100% in 2028 and after - Cost to achieve synergies in sheet "Synergies" will be 0% Perform the calculations in Euros in thousands and round to one decimal place.

Calculate the incremental Enterprise Value the Gerresheimer acquisition will add to the Aptar Group. Only reference the board presentation. Assume multiples for The Aptar Group remain constant and reference the acquisition multiple of 4.5x for Gerresheimer to arrive at the acquisition price. Use 2025E EBITDA. Do not incorporate synergies. Express your answer as a message right here. Give numbers in USD million, rounded to one decimal point.

Determine the effective interest rate of The Aptar Group acquiring Gerresheimer at a 35% premium. Then compare that effective interest rate to the effective interest rate of The Aptar Group as a standalone without acquisition. Use the board presentation to calculate the effective interest rates. Round the interest rates to one decimal point. Assume a 25% corporate tax rate. Create a New Sheet file with the Effective Interest Rate for Aptar Standalone and Aptar with Acquisition.

ATR is expecting to write down the goodwill related to Pharma to zero following the merger with GXI. Referring to the 2024 ATR 10K calculate the new total ending Goodwill under this write down scenario and output the number. Round it to the nearest thousand dollars. Tell me the information that I want in here.

Create a new Spreadsheet for me. Please compute a new Adjusted EBITDA value for the following companies: West Pharmaceutical, Stevanato Group, Schlott Pharma, Berry Global, Aptar Group using the board presentation, by taking the peer group median EBITDA margin and the corresponding revenue values. Multiply the Adjusted EBITDA values by the peer group median EBITDA multiple to derive a new Enterprise Value for each company. Report back the values. Display all margins and multiples to one decimal place and revenues, Adjusted EBITDA, and EVs to the nearest whole number, expressed in $mm.

Calculate the 2030E discounted EV/Revenue multiples for West Pharmaceutical, Stevanato Group, Schott Pharma, and Aptar Group. Reference the valuation model on the "Trading Comps" tab. Note that the financial and valuation metrics reflect 2025E assumptions. For each company, assume that the long-term revenue growth rate starting in 2026E is equal to its FY23 - FY24 YOY net sales growth rate, and the discount rates are as follows: West Pharmaceutical -> Reference WST 2024 10K for revenue growth -> Discount Rate: 9.4% Stevanato Group -> Reference Stevanto 2024 20-F for revenue growth -> Discount Rate: 8.8% Schott Pharma -> Reference Schott 2024 annual report for revenue growth -> Discount Rate: 10.0% Aptar Group -> Reference ATR 2024 10K for revenue growth -> Discount Rate: 7.4% Round the final output to one decimal and express it as a multiple. Print out what you find for me in here.

Reference 2024 ATR annual report to calculate Aptar Group's cash conversion cycle for FY2024, using FY2024 ending balance only. Output the cash conversion cycle in days, rounded to the nearest whole number. Respond with the information right here.

Calculate and report the adjusted diluted EPS growth for FY2023 to FY2024 for Amcor and unadjusted diluted EPS growth for The Aptar Group, rounded to the nearest whole percentage. Use the Amcor and ATR 2024 annual reports. Reply to me with the correct values here.